DGIdb - HDAC1 Gene Record

HDAC1 3065 Druggable GenomeClinically Actionable

Alternate Names:

3065
HISTONE DEACETYLASE 1
HDAC1
GON-10
HD1
RPD3
RPD3L1
601241
4852
ENSG00000116478
OTTHUMG00000007529
Q13547
HDAC
HDAC1_HUMAN
BE0008667
BE0002365
2658
PA29226
T68547
NP_004955
NM_004964

Gene Info:

Target Class	Enzymes
Target Subclass	EC:3.5.1.98
Target Main Class	Enzymes
Target Subclass	3.5.1.98
CancerCommons Reported Gene Name	HDAC
Gene Biotype	PROTEIN_CODING
GuideToPharmacology Gene Category Name	3.5.1.- Histone deacetylases (HDACs)
GuideToPharmacology Gene Category ID	848

(13 More Sources)

Gene Categories: Category Details

TRANSCRIPTION FACTOR BINDING
DRUGGABLE GENOME
CLINICALLY ACTIONABLE
ENZYME

Publications:

Mimori S et al., 2013, 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor., Bioorg Med Chem Lett
VanderMolen et al., 2011, Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma., J. Antibiot.
Hutt DM et al., 2010, Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis., Nat Chem Biol
Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
Geng et al., 2006, Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer., Cancer Res.
Beckers et al., 2007, Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group., Int. J. Cancer
Kiyokawa S et al., 2010, New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group., Bioorg Med Chem
Mai A et al., 2008, Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities., Bioorg Med Chem Lett
Souto JA et al., 2010, Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues., J Med Chem
Hirata Y et al., 2012, Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain., Bioorg Med Chem Lett
Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett
Hood K et al., 2016, Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma., J Adv Pract Oncol
Xu et al., 2007, Histone deacetylase inhibitors: molecular mechanisms of action., Oncogene
Grolla AA et al., 2009, Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases., J Med Chem
Yang W et al., 2015, Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors., Bioorg Med Chem
Guerrant W et al., 2013, Dual-acting histone deacetylase-topoisomerase I inhibitors., Bioorg Med Chem Lett
Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Neelarapu R et al., 2011, Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes., J Med Chem
Olson DE et al., 2013, Discovery of the first histone deacetylase 6/8 dual inhibitors., J Med Chem
Dallavalle S et al., 2009, Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors., Eur J Med Chem
Herman D et al., 2006, Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia., Nat Chem Biol
Perrino E et al., 2008, New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity., Bioorg Med Chem Lett
Petrelli R et al., 2014, From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine., Bioorg Med Chem Lett
Thomas M et al., 2008, Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy., Bioorg Med Chem
Marson CM et al., 2013, Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit., J Med Chem
Khan et al., 2008, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors., Biochem. J.
Marson CM et al., 2015, Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit., J Med Chem
Olsen CA et al., 2009, Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides., J Med Chem
Sodji QH et al., 2015, Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids., Eur J Med Chem
Fass et al., 2010, Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin., ACS Med Chem Lett
Benelkebir H et al., 2011, Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability., Bioorg Med Chem
Bhansali P et al., 2011, Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation., J Med Chem
Bhansali P et al., 2014, Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups., Eur J Med Chem
Klausmeyer P et al., 2011, Histone deacetylase inhibitors from Burkholderia thailandensis., J Nat Prod
Campbell CT et al., 2008, Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells., J Med Chem
Baud MG et al., 2012, Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets., J Med Chem
García J et al., 2011, Epigenetic profiling of the antitumor natural product psammaplin A and its analogues., Bioorg Med Chem
Hong S et al., 2015, Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents., Eur J Med Chem
Shi Y et al., 2007, Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition., Bioorg Med Chem Lett
Chen IH et al., 2009, Cytotoxic triterpenoids from the stems of Microtropis japonica., J Nat Prod
Marrazzo A et al., 2011, Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells., Eur J Med Chem
Schäfer S et al., 2008, Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs)., Bioorg Med Chem
Charrier C et al., 2009, Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression., J Med Chem
Bhuiyan MP et al., 2006, Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases., Bioorg Med Chem
Hait NC et al., 2015, The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer., Oncogenesis
Perla AS et al., 2020, Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells., Pediatr Hematol Oncol
Hait NC et al., 2014, Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory., Nat Neurosci
Zhang L et al., 2018, Zinc binding groups for histone deacetylase inhibitors., J Enzyme Inhib Med Chem

TUBASTATIN A HDAC1

Interaction Score: 2.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25899338

Sources:
DTC
CHEMBL152133 HDAC1

Interaction Score: 1.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
DEPUDECIN HDAC1

Interaction Score: 1.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CHLAMYDOCIN HDAC1

Interaction Score: 1.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CHEMBL152543 HDAC1

Interaction Score: 1.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
TUCIDINOSTAT HDAC1

Interaction Score: 1.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TTD GuideToPharmacology
FINGOLIMOD HDAC1

Interaction Score: 0.86

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
26053034 31826690 24859201

Sources:
DrugBank
MOCETINOSTAT HDAC1

Interaction Score: 0.82

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
17455259 23829483 17868033 26287310

Sources:
DTC TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
SPIRUCHOSTATIN C HDAC1

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21967146

Sources:
DTC
PANOBINOSTAT HDAC1

Interaction Score: 0.69

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
24694055 17145876 17455259

Sources:
CancerCommons DTC TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology
BELINOSTAT HDAC1

Interaction Score: 0.69

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PXD101

Novel drug target Established target

Notes

PMIDs:
25937017 28090369

Sources:
DTC TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions
ENTINOSTAT HDAC1

Interaction Score: 0.65

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name entinostat, SNDX-275, MS-275

Notes

PMIDs:
20452226 19966789 18381238 20491440 22321215

Sources:
DTC TdgClinicalTrial TTD TALC GuideToPharmacology ChemblInteractions
OBP-801 HDAC1

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
NANATINOSTAT HDAC1

Interaction Score: 0.54

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TTD TALC GuideToPharmacology
VORINOSTAT HDAC1

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
24694055 17694093 19344175 19966789 26211462 23622981 22260166 11752352 18381238 20491440 21548582 23672185 19084294

Sources:
TEND DTC TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions
ROMIDEPSIN HDAC1

Interaction Score: 0.48

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
21587264

Sources:
TEND TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions
TRICHOSTATIN HDAC1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21055848 16921367 18054239 19966789 22280363 19385600

Sources:
DTC
TACEDINALINE HDAC1

Interaction Score: 0.39

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Direct Interaction? False

Endogenous Drug? False

PMIDs:
18692397

Sources:
DTC GuideToPharmacology ChemblInteractions
ABEXINOSTAT HDAC1

Interaction Score: 0.39

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TdgClinicalTrial DrugBank TALC GuideToPharmacology
GIVINOSTAT HDAC1

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name ITF2357,Givinostat

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD TALC GuideToPharmacology
DOMATINOSTAT HDAC1

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name 4SC-202

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
SCRIPTAID HDAC1

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
19966789

Sources:
DTC TTD GuideToPharmacology
PSAMMAPLIN A HDAC1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22280363 21215647 25884112

Sources:
DTC
CUDC-101 HDAC1

Interaction Score: 0.31

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name CUDC-101

Mechanism of Interaction Histone deacetylase inhibitor

PMIDs:
None found

Sources:
TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions
APICIDIN HDAC1

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
19705846

Sources:
DTC GuideToPharmacology
RESMINOSTAT HDAC1

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
TdgClinicalTrial TTD GuideToPharmacology
CHIDAMIDE HDAC1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Chidamide, HBI-8000

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
PRACINOSTAT HDAC1

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TdgClinicalTrial DrugBank GuideToPharmacology
VALPROIC ACID HDAC1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18294844 16921367 25304896

Sources:
DTC
PHENYLBUTANOIC ACID HDAC1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24044874

Sources:
DTC TTD
CITARINOSTAT HDAC1

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
CHEMBL117487 HDAC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17566732

Sources:
DTC
CHEMBL1650245 HDAC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24044874

Sources:
DTC
BUTYRYLHYDROXAMIC ACID HDAC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21874153

Sources:
DTC
CHEMBL324053 HDAC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16921367

Sources:
DTC
PHENYLBUTYRYLHYDROXAMIC ACID HDAC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21874153

Sources:
DTC
SUBEROHYDROXAMIC ACID HDAC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16921367

Sources:
DTC
DACINOSTAT HDAC1

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
TTD GuideToPharmacology
LARGAZOLE HDAC1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21420302 21936551 25203782 20491440

Sources:
DTC
URSOLIC ACID HDAC1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19534471

Sources:
DTC
BUTANOIC ACID HDAC1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19053749

Sources:
DTC
RICOLINOSTAT HDAC1

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
DEPAKOTE HDAC1

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
AN-9 HDAC1

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
FIMEPINOSTAT HDAC1

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology ChemblInteractions
PANOBINOSTAT LACTATE HDAC1

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
QUISINOSTAT HDAC1

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
AR-42 HDAC1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AR-42

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
7-ETHYL-10-HYDROXYCAMPTOTHECIN HDAC1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23622981

Sources:
DTC
HINOKITIOL HDAC1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ZINC CHLORIDE HDAC1

Interaction Score: 0.03

Interaction Types & Directionality:

cofactor (activating)

Interaction Info:

PMIDs:
16439135 29616828

Sources:
DrugBank
DAUNORUBICIN HDAC1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
METHYLDOPA HDAC1

Interaction Score: 0.01

Interaction Types & Directionality:

cofactor (activating)

Interaction Info:

PMIDs:
16439135

Sources:
DrugBank

Ensembl: ENSG00000116478
- Version: 101_38
Alternate Names:

HDAC1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
CancerCommons: HDAC1
- Version: 25-July-2013
Alternate Names:

3065 Entrez Gene ID

Gene Info:

CancerCommons Reported Gene Name HDAC

Publications:
TdgClinicalTrial: Q13547
- Version: January-2014
Alternate Names:

HDAC1 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:3.5.1.98

Publications:
TEND: Q13547
- Version: 01-August-2011
Alternate Names:

3065 Entrez Gene Id

ENSG00000116478 Ensembl Gene Id

HDAC1 Gene Symbol

Gene Info:

Target Main Class Enzymes

Target Subclass 3.5.1.98

Publications:
GuideToPharmacology: 3065
- Version: 29-September-2020
Alternate Names:

4852 HUGO Gene ID

4852 HUGO Gene Symbol

histone deacetylase 1 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name 3.5.1.- Histone deacetylases (HDACs)

GuideToPharmacology Gene Category ID 848

Gene Categories:

ENZYME

Publications:

PharmGKB: HDAC1

Version: 18-August-2020

Alternate Names:

PA29226 PharmGKB ID

Gene Info:

Publications:

Kim MH et al., 2013, A polymorphism in the histone deacetylase 1 gene is associated with the response to corticosteroids in asthmatics., Korean J Intern Med

Ghodke-Puranik Y et al., 2013, Valproic acid pathway: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

DrugBank: BE0008667

Version: 5.1.7

Alternate Names:

HDAC1 DrugBank Gene Name

Q13547 UniProt Accession

3065 Entrez Gene Id

Gene Info:

Publications:

Hood K et al., 2016, Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma., J Adv Pract Oncol

Geng et al., 2006, Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer., Cancer Res.

Beckers et al., 2007, Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group., Int. J. Cancer

DrugBank: BE0002365

Version: 5.1.7

Alternate Names:

HDAC1 DrugBank Gene Name

Q13547 UniProt Accession

3065 Entrez Gene Id

Gene Info:

Publications:

Huang HS et al., 2010, Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes., Toxicol Appl Pharmacol

Bhuiyan MP et al., 2006, Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases., Bioorg Med Chem

VanderMolen et al., 2011, Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma., J. Antibiot.

DTC: HDAC1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem

Fass et al., 2010, Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin., ACS Med Chem Lett

Kiyokawa S et al., 2010, New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group., Bioorg Med Chem

HingoraniCasas: ENSG00000116478
- Version: 31-May-2017
Alternate Names:

ENSG00000116478 Gene Symbol

HDAC1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
MyCancerGenome: HDAC1
- Version: 20-Jun-2017
Alternate Names:

3065 Entrez Gene Id

HDAC1 MyCancerGenome Gene Symbol

HDAC MyCancerGenome Reported Gene Name

Gene Info:

Publications:
TALC: HDAC1
- Version: 12-May-2016
Alternate Names:

HDAC1 Gene Symbol

Gene Info:

Publications:
ChemblInteractions: RPD3L1
- Version: chembl_23
Alternate Names:

RPD3L1 GENE_SYMBOL

HDAC1 GENE_SYMBOL

Histone deacetylase 1 UNIPROT

Gene Info:

Publications:
GO: HDAC1
- Version: 05-September-2020
Alternate Names:

RPD3L1 GO Gene Synonym

Gene Info:

Gene Categories:

TRANSCRIPTION FACTOR BINDING

Publications:
Tempus: HDAC1
- Version: 11-November-2018
Alternate Names:

HDAC1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Histone deacetylase 1
- Version: 2020.06.01
Alternate Names:

HDAC1 TTD Gene Abbreviation

T68547 TTD Target ID

Gene Info:

Publications:
FoundationOneGenes: HDAC1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Novel drug target	Established target
Trial Name	entinostat, SNDX-275, MS-275
Notes

Notes
Trial Name	ITF2357,Givinostat
Novel drug target	Established target

Trial Name	Chidamide, HBI-8000
Novel drug target	Established target

Mechanism of Interaction	Histone deacetylase inhibitor
Direct Interaction	yes

3065	Entrez Gene Id
ENSG00000116478	Ensembl Gene Id
HDAC1	Gene Symbol

4852	HUGO Gene ID
4852	HUGO Gene Symbol
histone deacetylase 1	HUGO Gene Name

HDAC1	DrugBank Gene Name
Q13547	UniProt Accession
3065	Entrez Gene Id

RPD3L1	GENE_SYMBOL
HDAC1	GENE_SYMBOL
Histone deacetylase 1	UNIPROT

antagonist (inhibitory)
inhibitor (inhibitory)

HDAC1 Gene Record

HDAC1 3065 Druggable GenomeClinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25899338

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: None found

Sources: TTD GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 26053034 31826690 24859201

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: 17455259 23829483 17868033 26287310

Sources: DTC TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21967146

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: 24694055 17145876 17455259

Sources: CancerCommons DTC TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name PXD101 Novel drug target Established target Notes

PMIDs: 25937017 28090369

Sources: DTC TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name entinostat, SNDX-275, MS-275 Notes

PMIDs: 20452226 19966789 18381238 20491440 22321215

Sources: DTC TdgClinicalTrial TTD TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: TTD TALC GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: 24694055 17694093 19344175 19966789 26211462 23622981 22260166 11752352 18381238 20491440 21548582 23672185 19084294

Sources: TEND DTC TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 21587264

Sources: TEND TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21055848 16921367 18054239 19966789 22280363 19385600

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Direct Interaction? False Endogenous Drug? False

PMIDs: 18692397

Sources: DTC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

n/a

PMIDs:
25899338

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TTD GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
26053034 31826690 24859201

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
17455259 23829483 17868033 26287310

Sources:
DTC TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
21967146

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
24694055 17145876 17455259

Sources:
CancerCommons DTC TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PXD101

Novel drug target Established target

Notes

PMIDs:
25937017 28090369

Sources:
DTC TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name entinostat, SNDX-275, MS-275

Notes

PMIDs:
20452226 19966789 18381238 20491440 22321215

Sources:
DTC TdgClinicalTrial TTD TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TTD TALC GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
24694055 17694093 19344175 19966789 26211462 23622981 22260166 11752352 18381238 20491440 21548582 23672185 19084294

Sources:
TEND DTC TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
21587264

Sources:
TEND TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
21055848 16921367 18054239 19966789 22280363 19385600

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Direct Interaction? False

Endogenous Drug? False

PMIDs:
18692397

Sources:
DTC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TdgClinicalTrial DrugBank TALC GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name ITF2357,Givinostat

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD TALC GuideToPharmacology

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name 4SC-202

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
19966789

Sources:
DTC TTD GuideToPharmacology

Interaction Types & Directionality:

n/a